Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intervention A Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-68179280 in Healthy Participants

NCT04844463
View directory record Official record
Conditions
Healthy
Interventions
JNJ-68179280, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 26, 2026, 10:13 PM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GZR-18, Placebo
Drug · Other
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 26, 2026, 10:13 PM EDT
Withdrawn Phase 4 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures

NCT01231191
View directory record Official record
Conditions
Postoperative Pain, Intraoperative and Postoperative Opioid Requirements
Interventions
Intravenous acetaminophen, Intravenous placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

NCT00375518
View directory record Official record
Conditions
Thoracic Surgery
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 26, 2026, 10:13 PM EDT
Terminated Phase 4 Interventional Results available

Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

NCT03040024
View directory record Official record
Conditions
Otolaryngeal Cancer
Interventions
Ketamine, Placebo, Electroencephalogram (EEG)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

NCT00586820
View directory record Official record
Conditions
Myocardial Reperfusion Injury
Interventions
BQ-123, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Reducing the Effects of Aging on Cognition With Therapeutic Intervention of an Oral Nutrient (REACTION): A Pilot Trial

NCT04147624
View directory record Official record
Conditions
Cognitive Decline
Interventions
Souvenaid, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
55 Years to 89 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

NCT05487885
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution
Device · Behavioral · Drug
Lead sponsor
Erika Forbes
Other
Eligibility
15 Years to 25 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 26, 2026, 10:13 PM EDT
Not yet recruiting Not applicable Interventional

Home-Based Lower-Extremity Heat Therapy for Walking Function in Peripheral Artery Disease

NCT07653243
View directory record Official record
Conditions
PAD, PAD - Peripheral Arterial Disease
Interventions
Lower-Extremity Heat Therapy, Sham Lower-Extremity Heat Therapy
Device
Lead sponsor
Aquilo Sports, LLC
Industry
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

NCT04894071
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
QA102, Placebo
Drug
Lead sponsor
Smilebiotek Zhuhai Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Combination Nicotine Replacement for Alcoholic Smokers

NCT00064844
View directory record Official record
Conditions
Smoking, Alcoholism
Interventions
Cognitive Behavior Therapy for alcohol and smoking cessation, Nicoderm CQ nicotine patch, Placebo gum, Nicotine gum - Nicorette®
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Newington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 26, 2026, 10:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Ashwagandha Root Extract on Stress, Anxiety, and Sleep Quality in Adults Experiencing Minority Stress

NCT07441070
View directory record Official record
Conditions
Minority Stress, Psychological Stress, Anxiety
Interventions
Ashwagandha Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 26, 2026, 10:13 PM EDT
Not yet recruiting Phase 2 Interventional

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

NCT07588568
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Interventions
Upadacitinib 30mg Dose, Upadacitinib Matching Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 26, 2026, 10:13 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
View directory record Official record
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 26, 2026, 10:13 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Plantar Fasciitis

NCT05763381
View directory record Official record
Conditions
Plantar Fascitis
Interventions
Photobiomodulation Therapy (PBMT), Sham-Photobiomodualtion Therapy (Sham-PBMT)
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 26, 2026, 10:13 PM EDT
Recruiting Not applicable Interventional

The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers

NCT07415707
View directory record Official record
Conditions
Aging, Alcohol Drinking
Interventions
Visbiome, Motivational Interviewing, Placebo
Dietary Supplement · Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
65 Years to 84 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 26, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

Citalopram for Agitation in Alzheimer's Disease

NCT00898807
View directory record Official record
Conditions
Alzheimer's Disease, Agitation
Interventions
citalopram, placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
Not listed
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 26, 2026, 10:13 PM EDT
Active, not recruiting Not applicable Interventional

The Impact of Whey Protein on Frailty in Older Adults Classified as Pre-frail

NCT07167277
View directory record Official record
Conditions
Pre-frail, Pre-Frail Older Adults, Cognition, Physical Function, Dietary Intake Assessment, MRI
Interventions
Whey Protein, Placebo
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 26, 2026, 10:13 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

NCT06820177
View directory record Official record
Conditions
Abortion, Dilation and Evacuation, Hemorrhage, Prophylactic Tranexamic Acid Use, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Diego, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 26, 2026, 10:13 PM EDT